PARP1 and neoplasm: Since it has similar pharmacokinetic and pharmacodynamic properties as its parental drug, apart from its use as a PARP1 targeting tracer, it can also provide insights into the systemic behavior of olaparib with regard to tumor accumulation and therapeutic dosage.